定量检测 IL-2-HSA 融合蛋白双抗体夹心 ELISA 法的建立

目的:通过抗体配对方法,建立能高特异、高灵敏地定量检测食蟹猴体内 IL-2-HSA 融合蛋白浓度的双抗体夹心 ELISA 法.方法:以 IL-2单克隆抗体为包被抗体、IL-2-HSA 融合蛋白为夹心抗、生物素标记的 HSA 为检测抗体,一抗和二抗的工作浓度分别为8μg/mL 和1∶5000,HRP 标记的亲和素为1∶200.结果:IL-2-HSA 融合蛋白标准品的曲线范围为3.9~250 ng/mL,最低检测限为3.9 ng/mL,与 IL-2、HSA、GLP-1/HSA 和 CD20单抗均无交叉反应,方法的回收率为98.9%~101.5%,批内和批间准确度分别为96.1%~98.3%和93.9%~105.4%.结论:本方法符合新生物制品临床前药代动力学研究指导则的要求,可用 IL-2-HSA 融合蛋白在临床前药代动力学试验的定量检测.     

犬瘟热病毒（CDV）ELISA检测方法的建立与应用

目的建立犬CDV抗体ELISA检测方法。方法培养vero细胞,接种CDV病毒,制备vero正常抗原和CDV特异抗原,滴定酶结合物和抗原最佳工作浓度,并进行精密性、敏感性、稳定性、特异性实验。结果正常、特异抗原和酶结合物最佳工作浓度分别为1∶32 000、10μg/mL和1∶8 000;正常、特异抗原批内变异系数分别为9.1%和5.8%,批间平均变异系数分别为8.8%和6.6%;检测灵敏度为1∶2 560;与犬细小病毒（CPV）、犬肝炎病毒（ICHV）均无交叉反应。稳定性试验相对偏差小于25%。结论建立的ELISA方法重复性、稳定性好,特异性、敏感性强。可用于犬CDV抗体的检测。     

基于抗CD20单克隆抗体的2种夹心ELISA法的建立

目的:建立和比较2种灵敏、特异的夹心ELISA方法,用于准确定量检测食蟹猴血浆中重组抗CD20人源化单克隆抗体(rh-anti-CD20zumab)浓度。方法:以rh-anti-CD20zumab为基础,分别用山羊抗人IgG F(ab')2抗体和驴抗人IgG Fc抗体包被96孔酶标板,加入待测样品,均采用HRP标记的猴血清吸附的山羊抗人IgG抗体进行检测,加底物显色,读取D450nm值。结果:建立了2种定量检测rh-anti-CD20zumab的夹心ELISA方法并进行了确证,样品的前处理分别为1∶20和1∶10,方法的线性范围分别为40~5000和40~12 500 ng/mL,定量下限均为40 ng/mL,两者的板内、板间精密度分别小于16.2%和19.4%,准确度分别为-10.3%~16.6%和-14.4%~12.9%。2种方法均具有良好的特异性和稀释线性,且都未出现钩状效应。结论:方法学确证表明,本研究建立的2种ELISA法均符合新生物制品临床前药代动力学研究指导原则的要求,可用于rh-anti-CD20zumab的检测,为后续rh-anti-CD20zumab在食蟹猴体内的药代动力学研究提供了不同的检测方法。     

双抗体夹心ELISA检测HIV-1 gp41抗原方法的建立

目的:建立检测HIV-1gp41抗原的双抗体夹心ELISA,并探讨其临床应用的可行性。方法:用饱和硫酸铵(SAS)纯化抗HIV-1gp41-5单克隆抗体(mAb),用HRP标记后建立双抗体夹心ELISA法,对其灵敏度及特异性进行检测,并用该方法对40份HIV-1阳性血清进行了检测。结果:用mAbE12(5μg/mL)为包被抗体,2H6为酶标记抗体(1∶900)建立了双抗体夹心ELISA法,检测gp41-5多肽的灵敏度是100pg/mL。对HIV-1阳性血清中gp41抗原的检出率为67.5%(27/40)。结论:建立了特异性强、灵敏度良好的检测HIV-1gp41抗原的双抗体夹心ELISA法。     

肠道病毒71型抗原ELISA定量检测方法的建立及应用

目的建立肠道病毒71型(EV71)抗原ELISA定量检测方法,用于EV71疫苗生产工艺中抗原定量检测。方法选取抗EV71单克隆抗体作为包被抗体,HRP标记抗EV71多克隆抗体作为酶标二抗,建立EV71抗原ELISA定量检测方法。该方法经系统验证后,应用于定量检测2BS及Vero细胞基质EV71疫苗生产工艺过程样品的抗原含量。结果验证结果显示,该方法的线性范围为3.125~50.000 U/m L,样品回收率为92.0%~110.0%,变异系数小于8.8%;孵育时间及温度在一定范围内偏差的样品回收率为100.8%~113.8%;检测其他肠道病毒中抗原其A值均小于cut-off值;试剂于37℃孵育3 d后的检测样品回收率为101.4%~112.4%;2BS及Vero细胞基质EV71疫苗生产工艺过程样品的适用性检测中,抗原回收率为92.1%~114.9%。结论建立并验证EV71抗原ELISA定量检测方法,其准确度、精密度、耐用性均优良,特异性强、稳定性好,适用于不同细胞基质的EV71疫苗及多价手足口病疫苗生产工艺过程的质量控制。     

定量检测囊性纤维化跨膜传导调节因子BA-ELISA方法的建立与评价

目的:建立一种定量检测囊性纤维化跨膜传导调节因子(CFTR)的生物素-亲和素ELISA(BA-ELISA)方法并评价其可靠性。方法:优选设计CFTR三个表位的大肠杆菌表达抗原,免疫新西兰白兔获得CFTR多克隆抗体,用纯化后的抗体包被酶标板,并用生物素对其标记,从人精子提取CFTR作为抗原,用辣根过氧化物酶偶联的亲和素检测,优化两种抗体浓度及实验参数,建立可定量检测CFTR蛋白的双抗体夹心BA-ELISA方法;用临床精子标本评估所建立方法的重复性、特异性等。结果:CFTR包被抗体和生物素化CFTR抗体最适浓度分别为4μg/ml和10μg/ml,最佳封闭液为1%BSA-PBST,抗原与包被抗体最佳反应时间60 min,底物显色最佳时间15 min。批内、批间变异系数分别为2.16%~9.23%和2.29%~11.71%,包被的CFTR抗体与精子胞浆蛋白无交叉反应,最低检出下限为0.15 ng/ml,标准反应曲线具有良好的线性关系R2=0.962。结论:成功创建了定量检测CFTR蛋白的ELISA方法,具有特异性强、灵敏度高等特点。     

重组人鼠嵌合抗CD20单克隆抗体免疫原性检测方法的建立

目的:建立一种灵敏、特异、操作简单的ELISA方法,用于检测食蟹猴血清中抗CD20单克隆抗体的免疫原性。方法:首先采用桥连ELISA法对抗药物抗体(ADA)进行定性筛选,以抗CD20单克隆抗体作为包被抗体,以生物素标记的抗CD20单克隆抗体作为检测抗体,二者共同结合血清中存在的ADA,以D450/560nm值超过临界值作为阳性判断标准;初筛为阳性的样本采用免疫清除法进一步确证,并同时进行免疫交叉试验考察ADA对供试品和原研对照品的免疫反应有无差异。结果:建立了检测ADA的筛选方法和确证方法,确定了检测的临界值和归一化因子,血清中抗药物抗体的检测灵敏度达3.5 ng/m L,批内/批间精密度介于3.1%~7.4%,准确度介于-1.2%~9.5%;食蟹猴连续给药后,部分个体产生特异性抗体,且抗体滴度随时间延长而增高。结论:建立的ADA筛选方法和确证方法可用于毒性试验的免疫原性检测;动物给药剂量对抗体的产生有较大影响,低剂量连续给药更易诱发特异性抗体产生。     

乙型脑炎病毒（JEV）ELISA检测方法的建立

目的建立猪乙型脑炎病毒（JEV）抗体ELISA检测方法。方法培养BHK21细胞,接种JEV病毒,制备BHK21正常抗原和JEV特异抗原,滴定酶结合物和抗原最佳工作浓度,并进行精密性、敏感性、稳定性、特异性实验。结果正常、特异抗原和酶结合物最佳工作浓度分别为0.2μg/mL、10μg/mL和1∶20000;正常、特异抗原批内变异系数分别为8.3%和6.4%,批间平均变异系数分别为9.7%和11.5%;检测灵敏度为1∶1280;与猪瘟病毒（CSFV）、猪细小病毒（PPV）均无交叉反应。稳定性试验相对偏差小于25%。结论建立的ELISA方法重复性、稳定性好,特异性、敏感性强。可用于猪JEV抗体的检测。     

汉滩病毒PS-6单克隆抗体的制备及其双抗体夹心ELISA检测方法的建立与应用

目的 制备汉滩病毒(Hantaan virus, HTNV)PS-6株小鼠单克隆抗体(monoclonal antibody, mAb),建立HTNV抗原双抗体夹心ELISA检测方法,验证方法的检测性能并初步应用于疫苗抗原含量检测。方法 以HTNV PS-6株灭活全病毒原液作为免疫原,采用小鼠杂交瘤融合技术,筛选mAb杂交瘤细胞株,制备mAb;用间接ELISA测定mAb效价;用Western blot鉴定mAb特异性;用间接ELISA测定mAb相对亲和力;经抗体配对筛选,建立双抗体夹心ELISA病毒抗原检测方法。以I型肾综合征出血热疫苗标准品作为定量标准,验证该方法的检测限、线性范围、特异性、准确度、精密度;对6批次I型肾综合征出血热灭活疫苗原液进行检测,初步验证该方法的适用性。结果 获得4株稳定分泌抗HTNV PS-6特异性抗体的阳性杂交瘤细胞株：4B2、3H8、5D7及2A7;间接ELISA检测腹水抗体效价均在1×10⁶～1×106～1×10⁷;Western blot鉴定4株mAb均能特异性识别HTNV PS-6;相对亲和力为4B2>5D7>3H8>2A7;抗体ELISA配对筛选后,选用5D7作为包被抗体,4B2作为标记抗体,包被抗体工作浓度为10μg/mL,HRP标记抗体工作浓度为1∶5 000。该方法对HTNV PS-6抗原检测限为0.039 1μg/mL;检测线性范围为0.078 1～2.500 0μg/mL,R7;Western blot鉴定4株mAb均能特异性识别HTNV PS-6;相对亲和力为4B2>5D7>3H8>2A7;抗体ELISA配对筛选后,选用5D7作为包被抗体,4B2作为标记抗体,包被抗体工作浓度为10μg/mL,HRP标记抗体工作浓度为1∶5 000。该方法对HTNV PS-6抗原检测限为0.039 1μg/mL;检测线性范围为0.078 1～2.500 0μg/mL,R²> 0.97;检测与I型肾综合征出血热疫苗生产主要原辅料成分、II型肾综合征出血热疫苗、森林脑炎疫苗及甲肝疫苗均无交叉反应;准确度验证,病毒抗原回收率在95.8%～110.5%之间;试验内和试验间精密度,CV分别在6.72%～8.03%、8.24%～9.70%之间。用该方法检测6批次I型肾综合征出血热灭活疫苗原液,结果均呈剂量依赖性。结论 成功制备HTNV PS-6株mAb,建立病毒抗原双抗体夹心ELISA抗原检测方法,方法准确、可靠,可初步应用于I型肾综合征出血热灭活疫苗科研、生产过程病毒抗原检测。     

新型冠状病毒S蛋白抗体制备及双抗体夹心ELISA抗原检测方法的建立

由SARS-CoV-2(Severe acute respiratory syndrome coronavirus 2)引起的新型冠状病毒肺炎(Corona virus disease 2019,COVID-19)自2019年底暴发以来,已导致上亿人次感染和数百万人死亡,严重威胁着全人类的生命健康。为了建立一种能快速对新冠病毒疫苗中S蛋白抗原进行定量检测的方法,本研究通过免疫山羊制备多克隆抗体作为包被抗体,通过杂交瘤细胞技术制备了S蛋白特异性单克隆抗体并作为检测抗体,建立了双抗体夹心ELISA抗原检测方法,并验证其线性范围、敏感性、特异性、稳定性及符合率。结果显示,建立的双抗体夹心ELISA检测方法线性范围为1U~64U,相关系数R²大于0.99;特异性良好,敏感性为92.1%;批内和批间变异系数分别为2.5%~11.7%和1.3%~14.8%,检测已知背景样本符合率为96.7%。结果表明,该方法特异性好、敏感性高、且稳定性和准确性高,可用于新冠疫苗中S蛋白抗原含量测定。     

检测HSA—GLP-1融合蛋白双抗体夹心ELISA方法的建立

目的：为检测血清中HSA-GLP-1融合蛋白整体分子的浓度,建立一种特异、灵敏的定量检测食蟹猴体内HSA-GLP-1融合蛋白浓度的双抗体夹心ELISA的方法。方法：采用双抗体夹心ELISA方法,以GLP-1单克隆抗体为包被抗体、HSA-GLP-1融合蛋白为夹心抗原、anti-HSA-Biotin为检测抗体,用Streptavidin-HRP进行免疫放大,TMB显色。结果：建立了检测HSA-GLP-1融合蛋白的ELISA方法,其线性范围为15.6~1000 ng/mL,最低检测限为15.6 ng/mL,与GLP-1、HSA、IL2-HSA均无交叉反应,板内和板间精密度均小于15%,准确度为±15%,冻融稳定性和稀释稳定性良好。结论：建立的HSA-GLP-1蛋白检测方法符合新生物制品临床前药代动力学研究指导原则要求,可用于HSA-GLP-1融合蛋白在临床前药代动力学试验的定量检测。     

A radioimmunoassay for epinephrine and norepinephrine in tissues and plasma

An I¹²⁵ radioimmunoassay (RIA) has been developed for the measurement of plasma and tissue epinephrine (E) and norepinephrine (NE). The assay utilizes an antibody which specifically binds metanephrine. E and NE are detected by conversion to metanephrine with the enzymes catechol-0-methyltransferase and phenylethanol-amine-N-methyltransferase. The assay is very specific and will allow the measurement of E and NE in less than 500 μl of normal human plasma. E and NE concentrations were determined by both the RIA and a radioenzymatic assay in canine, human and rat biologic samples. The correlation coefficients between the two assays were .962 for E and .956 for NE. The RIA is sensitive, specific, precise and significantly less costly and time consuming than present radioenzymatic methods.     

重组人血清白蛋白抗体检测方法的建立及确证

目的：建立一种高灵敏度、高特异性、操作简单快捷、通量高的重组人血清白蛋白（rHSA）抗体检测方法。方法：采用桥连ELISA法,即将rHSA包被于96孔板,加入待测血样及阳性对照,用辣根过氧化物酶标记的rHSA检测,显色读取D_450nm/D_570nm值：用此方法确定临界值、方法灵敏度、精密度、血药浓度对检测方法的影响,再以免疫清除法进行确证。结果：通过桥连ELISA法确定临界值为0．0492,方法灵敏度为352ng／mL,方法板间、板内精密度均小于20％,且血药中的rHSA浓度为20μg／mL时不影响抗体的检测;经免疫清除法可将假阳性样本排除,从而提高了方法的特异性．结论：建立的方法可以准确、快速地检测出rHSA的特异性抗体。     

A rapid,sensitive, and easy-to-perform solid phase insulin radioimmunoassay

Accurate measurement of basal insulin release in perifusion, perfusion and low-density β-cell preparations has been difficult with present assays. A simple competitive, equilibrium, 15-hour insulin assay using ¹²⁵I-insulin with microtiter immobilized antubody, has been developed. This method, a Solid-phase-RadioImmunoAssay (SPRIA), is very sensitive and has a broad useful range (1 - 64 μU/ml). For a test series of 4 standard curves, interassay variation between controls of 1, 4, 16, and 64 μU/ml was ±5.2% (SEM) and intra-assay variation over the range of standards between 0.5 to 5.1% (SEM). Nonspecific binding was not significantly different from empty borosilicate culture tubes; 4.0 ± 0.4 and 3.5 ± 0.5 counts/minute (mean ± SEM; n = 54), respectively. This SPRIA can be used with existing γ-counters, while reducing the radioactive and glass waste presently produced by RIA (test-tube can be reused). The radioactive of unused test-tubes was compared againts test-tubes used for greater than 10 assays, values were 3.5 ± 0.5 and 4.4 ± 0.6 counts/minute (mean ± SEM; n = 54), respectively. Results of an oral glucose tolerance test (oGTT) performed on four male Wistar Fursth rats showed a close correlation between SPRIA and RIA insulin values (linear regression, r² = 0.990). This SPRIA measured plasma insulin levels from a human oGTT with a variation of ≤3.7% (SSEM0 between sample triplicates. Standard curves from the three commonly measured insulin isoforms (human, rat and porcine) showed a high correlation (mulitiple linear regression, r² = 0.998, n = 5 standard curves). In order to determine SPRIA's ability to measure acid extracts, insulin recovery from 2N acetic acid was compared against insulin recovery from Dullbecco's Modified Eagles medium (DME). The insulin recovery from 2N acetic acid was greater than 90% of that achieved with DME. in conclusion, an easy-to-perform assay which is deal for the rapid quantification of insulin from isolated islets of Langerhans, isolated β-cells, acetic acid extracts or plasma with greater sensitivity, and less waste than the conventional RIA has been developed.     

抗体偶联小分子药物T-DM1的ELISA检测方法的建立

目的:建立一种灵敏、特异、快速的ELISA方法,用于检测猕猴血清中T-DM1的含量。方法:采用双抗夹心ELISA法对T-DM1进行定量。以DM1单抗作为一抗包被到96孔板中,加入待检样品,之后再加入稀释好的猴血清吸附的羊抗人IgG-HRP(二抗),使之与结合到一抗上的T-DM1特异性结合,加底物显色,在酶标仪上读取D450nm值。结果:建立了检测T-DM1的ELISA方法并得到确证,方法的线性范围为0.625~80 ng/mL,定量下限为0.625 ng/mL,板内及板间精密度和准确度均在±15%以内,室温、冻融、稀释效应稳定性良好。结论:方法学验证表明ELISA法测定猴血清中T-DM1浓度的特异性、精密度和准确度均满足新生物制药临床前药代动力学研究指导原则要求,可用于T-DM1的检测。     

Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants

This method provides a simple extraction procedure, as well as a validated, sensitive, and specific liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of ampicillin, piperacillin, tazobactam, meropenem, acyclovir, and metronidazole in human plasma. The method was validated over concentration ranges specific for each compound, with a lower limit of quantification of 50-300 ng/mL and a sample volume of 50 μL. The method is accurate and precise, with within- and between-day accuracy ranging from 85 to 110% and 92 to 110%, respectively, and within- and between-day precision of 89-111% and 91-109%, respectively. Simplicity, low plasma volume, and high throughput make this method suitable for clinical pharmacokinetic studies in premature infants.     

A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study

A sensitive and rapid LC-MS/MS method was developed and validated for the determination of levamisole in human plasma. The assay was based on liquid-liquid extraction of analytes from human plasma with ethyl ether. Chromatographic separation was carried on an Agilent HC-C(8) column (150 mm × 4.6 mm, 5 μm) at 40°C, with a mobile phase consisting of acetonitrile-10 mM ammonium acetate (70:30, v/v), a flow rate of 0.5 mL/min and a total run time of 6 min. Detection and quantification were performed by mass spectrometry in the multiple reaction monitoring mode with positive electrospray ionization m/z at 205.1→178.2 for levamisole, and m/z 296.1→264.1 for mebendazole (internal standard). The assay was linear over a concentration range of 0.1-30 ng/mL with a lower limit of quantification of 0.1 ng/mL. The coefficient of variation of the assay precision was less than 8.5%. The assay was successfully used to analyze human plasma samples in a pharmacokinetic study where levamisole was administered as a liniment.     

定量检测猕猴血清中重组人源化抗狂犬病毒单克隆抗体间接ELISA法的建立

目的：建立定量检测血清中重组人源化抗狂犬病毒单克隆抗体（HuMabs）NM57的间接ELISA法,为药代动力学研究提供一种简单快速的方法。方法：采用狂犬病毒糖蛋白包被酶标板、HRP标记的IgG-Fc段为标记抗体,建立定量检测HuMabsNM57的间接ELISA法,并对其特异性、灵敏度、精密度及准确度进行检测。结果：间接ELISA法检测HuMabsNM57的灵敏度为5ng／mL,组内及组间精密度分别为2．6％-6．0％、8．5％-11．3％。结论：建立了灵敏度高、特异性强的检测HuMabs NM57的间接ELISA法,精密度及准确度均符合药代动力学要求,可用于猕猴及人血清中HuMabsNM57的检测。     

An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma

To support animal studies and clinical pharmacokinetic trials, we developed and validated an automated, specific and highly sensitive LC-MS/MS method for the quantification of naltrexone and 6beta-naltrexol in the same run. In human plasma, the assay had a lower limit of quantitation of only 5pg/mL. This was of critical importance to follow naltrexone pharmacokinetics during its terminal elimination phase. The assay had the following key performance characteristics for naltrexone in human plasma: range of reliable quantification: 0.005-100ng/mL (r2>0.99), inter-day accuracy (0.03ng/mL): 103.7% and inter-day precision: 10.1%. There were no ion suppression, matrix interferences or carry-over.     

Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma

A liquid chromatography-mass spectrometry (LC/MS) assay method was developed for the quantification of PSC 833 in rat plasma, using amiodarone as internal standard (IS). Separation was achieved using a C(8) 3.5 microm (2.1 mm x 50 mm) column heated to 60 degrees C with a mobile phase consisting of acetonitrile-ammonium hydroxide 0.2% (90:10 v/v) pumped at a rate of 0.2 mL/min. Detection was accomplished by mass spectrometer using selected ion monitoring (SIM) in positive mode. An excellent linear relationship was present between peak height ratios and rat plasma concentrations of PSC 833 ranging from 10 to 5000 ng/mL (R(2)>0.99). Intra-day and inter-day coefficients of variation (CV%) were less than 15%, and mean error was less than 10% for the concentrations above the limit of quantification. The validated limit of quantification of the assay was 10 ng/mL based on 0.1 mL rat plasma. The method limit of detection, based on an average signal-to-noise (S/N) ratio of 3, was found to be 2.5 ng/mL. The assay was capable of measuring the plasma concentrations of PSC 833 in rats injected with a single dose of 5 mg/kg of the drug. PSC 833 and IS eluted within 4 min, free of interfering peaks. The method was found to be fast, sensitive, and specific for the quantification of PSC 833 in rat plasma.